Jul 24th 2012 - Edison Investment Research today published a report on Omega Diagnostics (ODX.L, LSE:ODX, LON:ODX) entitled "Building Up The Franchise". In summary, the report says:
FY12 revenue, at £11.12m, was up 5% on a like-for-like basis, with an adjusted PBT of £1.0m and reported profit after tax of £0.32m. Development of a 40-50 launch test menu for allergy-iSYS is on track for a March 2013 launch. The Indian sales subsidiary traded from July 2012 and adds up to £448k of additional revenue in FY13. New Point of Care (PoC) tests for HIV monitoring and syphilis should be marketed from the first half of FY14. These are ideal for developing world use and could gain rapid government and NGO sales. There may be STD clinic use in developed markets.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »